Financial updates
Pharming Group reports second quarter and first half 2024 financial results and provides business update
Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2024.
- Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growth
- RUCONEST® second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023
- Joenja® (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024
- First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023
- On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)
- Overall cash and marketable securities declined to US$161.8 million at the end of the second quarter 2024 from US$203.5 million at the end of the first quarter 2024, primarily due to convertible bond refinancing
- Pharming to host a conference call today at 13:30 CEST (7:30 am EDT)
(view live webcast or register for the conference call)